JNJ

Pfizer launches biosimilar version of Amgen's Epogen
Pfizer launches biosimilar version of Amgen's Epogen
Biopharma Dive
Pfizer
biosimilars
Amgen
Epogen
JNJ
Procrit
anemia
Flag link:
New Jersey Sues Janssen Pharmaceuticals Over Two Opioid Drugs
New Jersey Sues Janssen Pharmaceuticals Over Two Opioid Drugs
BioSpace
New Jersey
opioids
JNJ
Janssen
Flag link:
J&J Vision inks $26m Singapore collaborative myopia research deal
J&J Vision inks $26m Singapore collaborative myopia research deal
Mass Device
JNJ
vision
Singapore
myopia
devices
Flag link:
Pa. State Judge orders new trial in J&J pelvic mesh case
Pa. State Judge orders new trial in J&J pelvic mesh case
Mass Device
JNJ
devices
pelvic mesh
Ethicon
Flag link:
In another try at lung cancer niche, J&J nabs a potential Tagrisso rival for $50M-plus
In another try at lung cancer niche, J&J nabs a potential Tagrisso rival for $50M-plus
Endpoints
JNJ
Tagrisso
AstraZeneca
Yuhan
Flag link:
[video+transcript]How Geron's Horrible Year Is a Great Reminder to Investors
[video+transcript]How Geron's Horrible Year Is a Great Reminder to Investors
Motley Fool
Geron
JNJ
imetelstat
Flag link:
Johnson & Johnson drops OSE’s rheumatoid arthritis drug
Johnson & Johnson drops OSE’s rheumatoid arthritis drug
Fierce Biotech
JNJ
OSE Immuotherapeutics
FR104
autoimmune disease
rheumatoid arthritis
Flag link:
Questions Raised About Invokana Label Expansion For CV Risk Reduction
Questions Raised About Invokana Label Expansion For CV Risk Reduction
Forbes
Janssen
JNJ
Invokana
type 2 diabetes
Flag link:
Johnson & Johnson bags long-awaited cardiovascular nod for diabetes drug Invokana
Johnson & Johnson bags long-awaited cardiovascular nod for diabetes drug Invokana
Fierce Pharma
JNJ
Invokana
type 2 diabetes
Flag link:
Arrowhead Pharmaceuticals Closes Agreements with Janssen Worth Up To $3.7 Billion
Arrowhead Pharmaceuticals Closes Agreements with Janssen Worth Up To $3.7 Billion
CP Wire
Arrowhead Pharmaceuticals
Janssen
JNJ
hepatitis B
Flag link:
Arrowhead Pharmaceuticals Closes Agreements with Janssen Worth Up To $3.7 Billion
Arrowhead Pharmaceuticals
Janssen
JNJ
Flag link:
Genmab and Johnson & Johnson’s Darzalex Dazzles in Multiple Myeloma Trial
Genmab and Johnson & Johnson’s Darzalex Dazzles in Multiple Myeloma Trial
BioSpace
JNJ
Janssen
Genmab
Darzalex
clinical trials
Multiple Myeloma
Flag link:
Janssen Unveils Positive Ph III Results for Symtuza in HIV-1 Patients
Janssen Unveils Positive Ph III Results for Symtuza in HIV-1 Patients
CP Wire
Janssen
JNJ
Symtuza
HIV
Flag link:
Johnson & Johnson to open JLabs virtual networking pod in Philadelphia
Johnson & Johnson to open JLabs virtual networking pod in Philadelphia
Fierce Biotech
JNJ
JLabs
JPod
innovation
Flag link:
Janssen Unveils Positive Ph III Results for Symtuza in HIV-1 Patients
Janssen
JNJ
Symtuza
HIV
Flag link:
Zytiga generics looming as US court nixes J&J patent
Zytiga generics looming as US court nixes J&J patent
Pharmaforum
JNJ
Zytiga
generics
prostate cancer
Flag link:
J&J steps up vaccines R&D—and preps for launches—with €72M plant
J&J steps up vaccines R&D—and preps for launches—with €72M plant
Fierce Pharma
JNJ
vaccines
drug manufacturing
Flag link:
Bayer plans filings for prostate cancer drug darolutamide
Bayer plans filings for prostate cancer drug darolutamide
Pharmaforum
Bayer
darolutamide
prostate cancer
Pfizer
JNJ
Flag link:
Stelara Shines in Three Year Crohn's Disease Study
Stelara Shines in Three Year Crohn's Disease Study
CP Wire
Janssen
JNJ
Stelara
Crohn's Disease
clinical trials
Flag link:
Stelara Shines in Three Year Crohn's Disease Study
Jannsen
JNJ
Stelara
Crohn's Disease
Flag link:

Pages